Wield Therapeutics is focused on developing genetics-driven solutions for autoimmune diseases. Led by an experienced team with a history of success in drug development, including innovative approvals and significant exits, Wield is committed to a fast, high probability of technical success (PTS) approach. Wield leverages genetic validation and predictive biomarkers to increase clinical success and shorten trial timelines.